SHA:603334 Revenue

In the year 2025, Suzhou Fengbei Biotech Stock had annual revenue of 3.17B CNY with 62.77% growth. Suzhou Fengbei Biotech Stock had revenue of 919.39M in the quarter ending December 31, 2025, with 63.89% growth.

Revenue

3.17B

Revenue Growth

+62.77%

P/S Ratio

2.28

Revenue / Employee

9.22M

Employees

344

Market Cap

7.22B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	3.17B	1.22B	62.77%
Dec 31, 2024	1.95B	220.23M	12.75%
Dec 31, 2023	1.73B	19.09M	1.12%
Dec 31, 2022	1.71B	413.11M	31.89%
Dec 31, 2021	1.30B	505.78M	64.04%
Dec 31, 2020	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Chengdu Kanghua Biological Products	1.20B
Jiangsu Aidea Pharmaceutical Group	719.17M
Anhui Huaheng Biotechnology	2.95B
Wuhan Keqian Biology Co.,Ltd	949.74M
Shanghai OPM Biosciences	354.91M
Nanjing Vazyme Biotech	1.41B
Acrobiosystems	887.21M
Xiangxue Pharmaceutical	1.47B

Revenue Rankings